Athenex (OTCPK:ATNX.Q) - Aandelenkoers, Nieuws & Analyse

ATNX.Q Overzicht aandelen

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

Over het bedrijf

ATNX.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Does not have a meaningful market cap ($132K)

Negative shareholders equity

Highly volatile share price over the past 3 months

Earnings have declined by 7.6% per year over past 5 years

+ 1 meer risico

Athenex, Inc. Concurrenten

Endonovo Therapeutics

OTCPK:ENDV

US$408.7k

Bellerophon Therapeutics

OTCPK:BLPH

US$440.4k

NovelStem International

OTCPK:NSTM

US$473.5k

Capstone Holding

OTCPK:CAPS

US$504.4k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Athenex
Historische aandelenkoersen
Huidige aandelenkoers	US$0.015
52 Week Hoogtepunt	US$6.00
52 Week Laag	US$0.0003
Bèta	0.79
11 maand verandering	52.00%
3 maanden verandering	-86.19%
1 Jaar Verandering	-99.72%
33 jaar verandering	-99.99%
5 jaar verandering	-99.99%
Verandering sinds IPO	-99.99%

Recent nieuws en updates

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

Rendement voor aandeelhouders

	ATNX.Q	US Biotechs	US Markt
7D	0%	-0.7%	-1.6%
1Y	-99.7%	19.8%	30.8%

Rendement versus industrie: ATNX.Q underperformed the US Biotechs industry which returned -3.5% over the past year.

Rendement versus markt: ATNX.Q underperformed the US Market which returned 15.2% over the past year.

Prijsvolatiliteit

Is ATNX.Q's price volatile compared to industry and market?
ATNX.Q volatility
ATNX.Q Average Weekly Movement	339.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ATNX.Q's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: ATNX.Q's weekly volatility has increased from 167% to 339% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Athenex zich tot de beurswaarde?
ATNX.Q fundamentele statistieken
Marktkapitalisatie	US$131.68k
Inkomsten(TTM)	-US$97.98m
Inkomsten(TTM)	US$102.82m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is ATNX.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ATNX.Q resultatenrekening (TTM)
Inkomsten	US$102.82m
Kosten van inkomsten	US$76.12m
Brutowinst	US$26.70m
Overige uitgaven	US$124.68m
Inkomsten	-US$97.98m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-11.31
Brutomarge	25.97%
Nettowinstmarge	-95.29%
Schuld/Eigen Vermogen Verhouding	-511.7%

Hoe presteerde ATNX.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

ATNX.Q Overzicht aandelen

Beloningen

Risicoanalyse

Athenex, Inc. Concurrenten

OTCPK:ENDV

US$408.7k

OTCPK:BLPH

US$440.4k

OTCPK:NSTM

US$473.5k

OTCPK:CAPS

US$504.4k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021